LanZhou Foci Pharmaceutical Co.,Ltd.
SZSE:002644.SZ
9.53 (CNY) • At close October 23, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 1,163.134 | 1,019.176 | 817.641 | 668.051 | 628.815 | 544.581 | 501.14 | 363.255 | 327.584 | 399.071 | 291.528 | 266.362 | 271.184 | 262.406 | 232.209 | 219.012 | 177.49 |
Cost of Revenue
| 801.839 | 732.964 | 594.494 | 502.661 | 461.623 | 369.734 | 352.086 | 255.015 | 244.927 | 310.706 | 187.658 | 179.48 | 177.99 | 167.481 | 144.171 | 131.811 | 104.86 |
Gross Profit
| 361.296 | 286.212 | 223.146 | 165.39 | 167.192 | 174.847 | 149.053 | 108.24 | 82.658 | 88.366 | 103.871 | 86.882 | 93.194 | 94.925 | 88.038 | 87.201 | 72.63 |
Gross Profit Ratio
| 0.311 | 0.281 | 0.273 | 0.248 | 0.266 | 0.321 | 0.297 | 0.298 | 0.252 | 0.221 | 0.356 | 0.326 | 0.344 | 0.362 | 0.379 | 0.398 | 0.409 |
Reseach & Development Expenses
| 30.927 | 23.556 | 19.357 | 15.383 | 20.645 | 19.517 | 17.398 | 13.485 | 10.009 | 10.105 | 10.904 | 9.89 | 7.464 | 4.505 | 3.313 | 2.522 | 0 |
General & Administrative Expenses
| 63.372 | 11.427 | 9.569 | 9.331 | 12.555 | 5.731 | 4.351 | 4.714 | 4.827 | 3.706 | 4.796 | 2.5 | 3.055 | 3.095 | 3.261 | 3.52 | 11.584 |
Selling & Marketing Expenses
| 111.438 | 104.138 | 81.266 | 71.212 | 91.223 | 64.541 | 45.049 | 29.472 | 25.798 | 31.663 | 35.826 | 28.843 | 31.037 | 35.276 | 34.887 | 35.217 | 24.03 |
SG&A
| 174.81 | 115.565 | 90.836 | 80.543 | 103.778 | 70.273 | 49.4 | 34.187 | 30.626 | 35.369 | 40.623 | 31.342 | 34.092 | 38.371 | 38.149 | 38.738 | 35.613 |
Other Expenses
| 72.284 | -9.747 | 24.363 | 13.431 | -26.088 | 0.336 | 2.159 | 6.278 | 7.643 | 10.946 | 9.514 | 6.91 | 4.758 | 24.045 | 13.538 | 1.259 | -0.398 |
Operating Expenses
| 278.021 | 129.373 | 134.555 | 109.357 | 98.335 | 112.824 | 89.309 | 74.119 | 65.32 | 67.508 | 71.567 | 55.486 | 55.775 | 57.48 | 56.096 | 56.709 | 38.027 |
Operating Income
| 83.275 | 139.401 | 112.362 | 64.433 | 78.242 | 86.143 | 85.217 | 64.682 | 41.471 | 28.436 | 26.242 | 27.603 | 31.532 | 31.664 | 27.067 | 24.948 | 27.704 |
Operating Income Ratio
| 0.072 | 0.137 | 0.137 | 0.096 | 0.124 | 0.158 | 0.17 | 0.178 | 0.127 | 0.071 | 0.09 | 0.104 | 0.116 | 0.121 | 0.117 | 0.114 | 0.156 |
Total Other Income Expenses Net
| -1.633 | -12.43 | -1.548 | 0.184 | -4.23 | -1.238 | 2.159 | 5.907 | 7.614 | 10.911 | 9.514 | 6.908 | 4.758 | 24.045 | 13.538 | 1.259 | -0.398 |
Income Before Tax
| 81.642 | 126.997 | 110.814 | 130.523 | 78.733 | 86.479 | 87.376 | 70.589 | 49.085 | 39.347 | 35.755 | 34.511 | 36.291 | 55.709 | 40.605 | 26.207 | 27.306 |
Income Before Tax Ratio
| 0.07 | 0.125 | 0.136 | 0.195 | 0.125 | 0.159 | 0.174 | 0.194 | 0.15 | 0.099 | 0.123 | 0.13 | 0.134 | 0.212 | 0.175 | 0.12 | 0.154 |
Income Tax Expense
| 13.52 | 21.069 | 17.296 | 22.812 | 7.811 | 13.56 | 13.283 | 9.663 | 6.138 | 4.694 | 5.159 | 4.155 | 4.23 | 4.467 | 4.458 | 4.598 | 3.994 |
Net Income
| 67.19 | 108.654 | 93.259 | 108.018 | 71.107 | 72.918 | 74.093 | 60.926 | 42.948 | 34.653 | 30.596 | 30.356 | 32.061 | 51.242 | 36.147 | 21.609 | 23.313 |
Net Income Ratio
| 0.058 | 0.107 | 0.114 | 0.162 | 0.113 | 0.134 | 0.148 | 0.168 | 0.131 | 0.087 | 0.105 | 0.114 | 0.118 | 0.195 | 0.156 | 0.099 | 0.131 |
EPS
| 0.13 | 0.21 | 0.18 | 0.21 | 0.15 | 0.14 | 0.15 | 0.12 | 0.091 | 0.097 | 0.069 | 0.068 | 0.096 | 0.15 | 0.11 | 0.066 | 0.069 |
EPS Diluted
| 0.13 | 0.21 | 0.18 | 0.21 | 0.15 | 0.14 | 0.15 | 0.12 | 0.091 | 0.097 | 0.069 | 0.068 | 0.096 | 0.15 | 0.11 | 0.066 | 0.069 |
EBITDA
| 135.369 | 190.352 | 161.95 | 58.417 | 141.097 | 123.242 | 110.032 | 89.367 | 68.246 | 37.01 | 56.811 | 60.441 | 51.197 | 70.549 | 43.169 | 43.835 | 37.365 |
EBITDA Ratio
| 0.116 | 0.198 | 0.177 | 0.154 | 0.225 | 0.226 | 0.223 | 0.248 | 0.204 | 0.142 | 0.203 | 0.205 | 0.177 | 0.277 | 0.249 | 0.207 | 0.211 |